Tyra Biosciences (TYRA) Total Current Liabilities (2020 - 2026)
Quarterly Total Current Liabilities rose 35.17% to $19.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $19.3 million through Mar 2026, up 35.17% year-over-year, with the annual reading at $18.1 million for FY2025, 23.98% up from the prior year.
Tyra Biosciences filings provide 7 years of Total Current Liabilities readings, the most recent being $19.3 million for Q1 2026.
- Total Current Liabilities hit $19.3 million in Q1 2026 for Tyra Biosciences, up from $18.1 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $19.3 million in Q1 2026 and bottomed at $3.7 million in Q1 2023.
- Average Total Current Liabilities over 5 years is $10.8 million, with a median of $10.4 million recorded in 2024.
- Peak annual rise in Total Current Liabilities hit 168.95% in 2023, while the deepest fall reached 24.87% in 2023.
- Tyra Biosciences' Total Current Liabilities stood at $5.7 million in 2022, then skyrocketed by 168.95% to $15.3 million in 2023, then dropped by 4.82% to $14.6 million in 2024, then grew by 23.98% to $18.1 million in 2025, then grew by 6.42% to $19.3 million in 2026.
- Per Business Quant, the three most recent readings for TYRA's Total Current Liabilities are $19.3 million (Q1 2026), $18.1 million (Q4 2025), and $15.9 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | 16.35 Mn |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | 1.70 Mn |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | 636.40 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | 66.94 Mn |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | 13.42 Mn |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 3.88 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 5.11 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 1.35 Bn |
| 10 | Tyra Biosciences | 2.03 Bn | 2.03 Bn | - | 19.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 19.26 Mn |
| Dec 31, 2025 | 18.09 Mn |
| Sep 30, 2025 | 15.88 Mn |
| Jun 30, 2025 | 13.77 Mn |
| Mar 31, 2025 | 14.25 Mn |
| Dec 31, 2024 | 14.59 Mn |
| Sep 30, 2024 | 12.37 Mn |
| Jun 30, 2024 | 10.38 Mn |
| Mar 31, 2024 | 8.72 Mn |
| Dec 31, 2023 | 15.33 Mn |
| Sep 30, 2023 | 10.15 Mn |
| Jun 30, 2023 | 5.41 Mn |
| Mar 31, 2023 | 3.68 Mn |
| Dec 31, 2022 | 5.70 Mn |
| Sep 30, 2022 | 5.49 Mn |
| Jun 30, 2022 | 5.46 Mn |
| Mar 31, 2022 | 4.90 Mn |
| Dec 31, 2021 | 3.62 Mn |
| Sep 30, 2021 | 4.77 Mn |
| Dec 31, 2020 | 1.86 Mn |